BGMS Bio Green Med Solution Forward P/S Multiple

cyclacel.com (BGMS) - corporate logo

The forward P/S ratio reflects market revenue expectations for Bio Green Med Solution Inc (BGMS), where the current parameter is 2.50. The business relies on external contractors for synthesis and testing. Targeted alliances with funds complement a strategy of standalone trials. Ultimate success is based on patent protection and the clinical trial results of targeted drugs.

BGMS (cyclacel.com) Price to Expected Revenue Ratio history from 09/13/2025 to 11/13/2026

Cyclacel - analytical breakdowns and key metrics (BGMS)

- current price and projected stock value:
Stock Price Bio Green Med Solution|BGMS - Analyst Target Range
- market capitalization data:
Market Capitalization Cyclacel|BGMS - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Bio Green Med Solution|BGMS - Total Net Assets|Market Capitalization to Book Value Ratio cyclacel.com|BGMS - Company Assets
- debt and liquidity data:
Total Debt to Capital Bio Green Med Solution Inc|BGMS - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Bio Green Med Solution Inc|BGMS - Aggregate Debt Obligations|Debt to Book Value Cyclacel|BGMS - Amount of Long-Term Liabilities|Company Short-Term Debts Bio Green Med Solution|Quick Ratio cyclacel.com
- net income and valuation multiples indicators:
BGMS - Company Net Income|Expected Profit Bio Green Med Solution Inc|BGMS - Company Value to Net Income|Forward P/E Multiple Cyclacel Pharmaceuticals|BGMS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclacel|BGMS - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Bio Green Med Solution|BGMS - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth cyclacel.com|BGMS - Earnings per share growth in current year|Earnings growth forecast for next year Bio Green Med Solution Inc
- issuer revenue and sales details:
BGMS - Company Gross Revenue|Company Projected Revenue Bio Green Med Solution|BGMS - Price to Sales|Forward Price-to-Revenue Multiple Cyclacel
Summary company analysis:Bio Green Med Solution (BGMS)
Product sample of cyclacel.com

Minimizing investment risks requires an analysis of projected revenue, particularly when geopolitical barriers and disrupted medtech supply chains create revenue uncertainty for Bio Green Med Solution Inc (BGMS). The ratio of market capitalization to expected sales, as reflected in the forward P/S history, allows investors to determine the degree of overpayment for the asset and assess the impact of liquidity on the business valuation.

Competing companies

Forward P/S Multiple GMAB (Genmab)|Projected Price to Revenue Exelixis Inc|Nuvalent Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kymera Corp|IDYA (IDEAYA Biosciences) - Forward Price-to-Revenue Multiple|ELVN: Price to Expected Revenue Ratio|ORIC (ORIC Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Relay Therapeutics Inc RLAY|Forward P/S Multiple NRIX|Tyra Corp - Market Cap to Projected Revenue|Verastem, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales GLUE|CGEM: Forward Price-to-Revenue Multiple|Immuneering Corp - Price to Expected Revenue Ratio|CCCC: Forward P/S Multiple|Black Diamond Therapeutics, Inc - Forward Price to Sales|RPTX (Repare Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio pmvpharma.com PMVP|Price-to-Projected Revenue Ratio Karyopharm Therapeutics (KPTI)|PPCB (propanc.com) - Forward Price to Sales|Forward P/S Multiple AADI (Aadi Bioscience, Inc.)|Forward P/S Multiple Aileron Therapeutics Inc ALRN|BPMC - Price-to-Projected Revenue Ratio|Future Price to Revenue GLYC|SWTX (SpringWorks Therapeutics, Inc.) - Forward Price-to-Revenue Multiple